Saturday, July 11, 2026

pharma · Head and Neck Neoplasms · Rheumatoid Arthritis

Chinese University of

Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility D

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
55
Patents
0
Clinical program

Per-Oral Endoscopic Myotomy

Phase 2 · other · Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES

Per-Oral Endoscopic Myotomy for Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES is a Phase 2 program (other) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).

Internal code CRE-2010.430

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chinese University of Hong Kong
Phase
Phase 2
Modality
other
Indication
Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES
Status
active
Trials
1

Clinical trials